

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mark Tawa et al.

Serial No. : 10/541,216

Art Unit: 1618

Filed : June 29, 2005

Examiner: E.E. Silverman

For : PHARMACEUTICAL COMPOSITIONS WITH IMPROVED
DISSOLUTION

CERTIFICATE OF EFS TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted to the United States Patent and Trademark Office on the date shown below via the "Electronic Filing System" in accordance with 37 C.F.R. § 1.6(a)(4).

Kristin Miele
Type or print name

/Kristin Miele/
Signature

May 18, 2009
Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statements filed on November 17, 2006 and January 29, 2007.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TP/5013USPCT6/JML.

Respectfully submitted,

Date: May 18, 2009
TransForm Pharmaceuticals, Inc.
29 Hartwell Avenue
Lexington, MA 02421
Telephone: (732) 524-1106
Facsimile: (732) 524-5008

By: /Jamie M. Larmann/
Jamie M. Larmann, Patent Attorney
Reg. No. 48,623
Customer No. 27777